ZTE and HISTO PATH sign a strategic cooperation agreement on 5G
Release Date：2020-06-08 Author：ZTE Click：304
08 June 2020, Shenzhen, China - ZTE Corporation (0763.HK / 000063.SZ), a major international provider of telecommunications, enterprise and consumer technology solutions for the Mobile Internet, today has signed a strategic cooperation agreement on 5G with HISTO PATH, the first independent third-party pathological diagnosis center in China. The agreement aims to further improve the speed and quality of data transmission in the digital remote pathological diagnosis service, and fundamentally solve the definition and timeliness problems of image transmission.
As per the agreement, ZTE and HISTO PATH will build China’s first 5G-based pathological diagnosis service network, which will ensure real-time collaboration of remote pathology diagnosis in different places, satisfying pathology’s requirements for high-definition images in diagnosis, teaching and data storage. By virtue of the new 5G-based pathological diagnosis service network, quick diagnosis, daily consultation, remote teaching will be fully upgraded, accelerating comprehensive service innovation and greatly improving the efficiency of diagnosis and surgery of cooperative hospitals.
In addition, with the technical support of ZTE and the Yingtan Branch of China Telecom, HISTO PATH has connected with a hospital in Jiangxi Province to demonstrate the 5G-based remote dissection instruction and 5G+4K-based video conferencing remote diagnostics.
“The cooperation with ZTE will continue to help HISTO PATH promote theintensive, centralized, digital, and intelligent pathological diagnosis capabilities on a national scale,” said Zhu Dawei, Co-founder and Chairman of HISTO PATH. “That will facilitate the implementation of graded diagnosis and accurate diagnosis of China’s medical reform.”
“It is very inspiring to see 5G technologies implemented in the medical field to provide people with more valuable services for their healthy lives,” said Zhu Yongtao, ZTE’s Senior Vice President. “We hope that both parties will deepen 5G cooperation in the field of health care, jointly explore various industrial applications, and set a good example for the cross-industry cooperation in 5G and health care arenas.”
Moving forward, ZTE and HISTO PATH will fully leverage the advantages in their respective fields, jointly build a solution library, explore the potential market of the medical industry, and set up 5G+ medical industry application demonstrations, expecting to promote the digital and intelligent transformation of the pathological diagnosis industry.
ZTE is a provider of advanced telecommunications systems, mobile devices and enterprise technology solutions to consumers, operators, companies and public sector customers. As a part of ZTE’s strategy, the company is committed to providing customers with integrated end-to-end innovations to deliver excellence and value as the telecommunications and information technology sectors converge. Listed in the stock exchanges of Hong Kong and Shenzhen (H share stock code: 0763.HK / A share stock code: 000063.SZ), ZTE sells its products and services in more than 160 countries.
To date, ZTE has obtained 35 commercial 5G contracts in major markets, such as Europe, Asia Pacific, Middle East and Africa (MEA). ZTE commits 10 percent of its annual revenues to research and development and takes leadership roles in international standard-setting organizations.